MedinCell S.A.
MedinCell S.A. (MEDCL.PA) Stock Competitors & Peer Comparison
See (MEDCL.PA) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MEDCL.PA | €17.25 | +0.82% | 570.6M | -15.83 | -€1.09 | N/A |
| UCB.BR | €178.85 | +0.39% | 34B | 32.58 | €5.49 | +0.67% |
| ARGX.BR | €511.80 | +1.55% | 31.3B | 36.66 | €13.96 | N/A |
| TUB.BR | €142.00 | -0.28% | 6.3B | 70.30 | €2.02 | +0.63% |
| ABVX.PA | €57.00 | +0.00% | 3.6B | -19.32 | -€2.95 | N/A |
| GLPG.AS | €28.46 | +4.63% | 1.9B | -6.50 | -€4.38 | N/A |
| GTBP.PA | €280.50 | +0.00% | 626.7M | -4.10 | -€68.39 | N/A |
| PHARM.AS | €0.87 | +1.05% | 596.1M | -43.50 | -€0.02 | N/A |
| VLA.PA | €3.24 | +0.06% | 550.3M | -5.78 | -€0.56 | N/A |
| IVA.PA | €2.75 | -0.36% | 382.5M | -0.89 | -€3.08 | N/A |
Stock Comparison
MEDCL.PA vs UCB.BR Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, UCB.BR has a market cap of 34B. Regarding current trading prices, MEDCL.PA is priced at €17.25, while UCB.BR trades at €178.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas UCB.BR's P/E ratio is 32.58. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to UCB.BR's ROE of +0.11%. Regarding short-term risk, MEDCL.PA is more volatile compared to UCB.BR. This indicates potentially higher risk in terms of short-term price fluctuations for MEDCL.PA.Check UCB.BR's competition here
MEDCL.PA vs ARGX.BR Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, ARGX.BR has a market cap of 31.3B. Regarding current trading prices, MEDCL.PA is priced at €17.25, while ARGX.BR trades at €511.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas ARGX.BR's P/E ratio is 36.66. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to ARGX.BR's ROE of +0.17%. Regarding short-term risk, MEDCL.PA is more volatile compared to ARGX.BR. This indicates potentially higher risk in terms of short-term price fluctuations for MEDCL.PA.Check ARGX.BR's competition here
MEDCL.PA vs TUB.BR Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, TUB.BR has a market cap of 6.3B. Regarding current trading prices, MEDCL.PA is priced at €17.25, while TUB.BR trades at €142.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas TUB.BR's P/E ratio is 70.30. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to TUB.BR's ROE of +0.05%. Regarding short-term risk, MEDCL.PA is more volatile compared to TUB.BR. This indicates potentially higher risk in terms of short-term price fluctuations for MEDCL.PA.Check TUB.BR's competition here
MEDCL.PA vs ABVX.PA Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, ABVX.PA has a market cap of 3.6B. Regarding current trading prices, MEDCL.PA is priced at €17.25, while ABVX.PA trades at €57.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas ABVX.PA's P/E ratio is -19.32. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to ABVX.PA's ROE of -2.11%. Regarding short-term risk, MEDCL.PA is less volatile compared to ABVX.PA. This indicates potentially lower risk in terms of short-term price fluctuations for MEDCL.PA.Check ABVX.PA's competition here
MEDCL.PA vs GLPG.AS Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, GLPG.AS has a market cap of 1.9B. Regarding current trading prices, MEDCL.PA is priced at €17.25, while GLPG.AS trades at €28.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas GLPG.AS's P/E ratio is -6.50. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to GLPG.AS's ROE of -0.06%. Regarding short-term risk, MEDCL.PA is less volatile compared to GLPG.AS. This indicates potentially lower risk in terms of short-term price fluctuations for MEDCL.PA.Check GLPG.AS's competition here
MEDCL.PA vs GTBP.PA Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, GTBP.PA has a market cap of 626.7M. Regarding current trading prices, MEDCL.PA is priced at €17.25, while GTBP.PA trades at €280.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas GTBP.PA's P/E ratio is -4.10. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to GTBP.PA's ROE of -4.68%. Regarding short-term risk, MEDCL.PA is less volatile compared to GTBP.PA. This indicates potentially lower risk in terms of short-term price fluctuations for MEDCL.PA.Check GTBP.PA's competition here
MEDCL.PA vs PHARM.AS Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, PHARM.AS has a market cap of 596.1M. Regarding current trading prices, MEDCL.PA is priced at €17.25, while PHARM.AS trades at €0.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas PHARM.AS's P/E ratio is -43.50. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to PHARM.AS's ROE of -0.06%. Regarding short-term risk, MEDCL.PA is more volatile compared to PHARM.AS. This indicates potentially higher risk in terms of short-term price fluctuations for MEDCL.PA.Check PHARM.AS's competition here
MEDCL.PA vs VLA.PA Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, VLA.PA has a market cap of 550.3M. Regarding current trading prices, MEDCL.PA is priced at €17.25, while VLA.PA trades at €3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas VLA.PA's P/E ratio is -5.78. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to VLA.PA's ROE of -0.43%. Regarding short-term risk, MEDCL.PA is less volatile compared to VLA.PA. This indicates potentially lower risk in terms of short-term price fluctuations for MEDCL.PA.Check VLA.PA's competition here
MEDCL.PA vs IVA.PA Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, IVA.PA has a market cap of 382.5M. Regarding current trading prices, MEDCL.PA is priced at €17.25, while IVA.PA trades at €2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas IVA.PA's P/E ratio is -0.89. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to IVA.PA's ROE of +1.98%. Regarding short-term risk, MEDCL.PA is less volatile compared to IVA.PA. This indicates potentially lower risk in terms of short-term price fluctuations for MEDCL.PA.Check IVA.PA's competition here
MEDCL.PA vs NANO.PA Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, NANO.PA has a market cap of 268.1M. Regarding current trading prices, MEDCL.PA is priced at €17.25, while NANO.PA trades at €5.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas NANO.PA's P/E ratio is -3.95. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to NANO.PA's ROE of +0.77%. Regarding short-term risk, MEDCL.PA is less volatile compared to NANO.PA. This indicates potentially lower risk in terms of short-term price fluctuations for MEDCL.PA.Check NANO.PA's competition here
MEDCL.PA vs DBV.PA Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, DBV.PA has a market cap of 234.1M. Regarding current trading prices, MEDCL.PA is priced at €17.25, while DBV.PA trades at €1.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas DBV.PA's P/E ratio is -1.75. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to DBV.PA's ROE of -2.68%. Regarding short-term risk, MEDCL.PA is less volatile compared to DBV.PA. This indicates potentially lower risk in terms of short-term price fluctuations for MEDCL.PA.Check DBV.PA's competition here
MEDCL.PA vs ORY.MC Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, ORY.MC has a market cap of 210.8M. Regarding current trading prices, MEDCL.PA is priced at €17.25, while ORY.MC trades at €2.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas ORY.MC's P/E ratio is -45.33. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to ORY.MC's ROE of -0.04%. Regarding short-term risk, MEDCL.PA is less volatile compared to ORY.MC. This indicates potentially lower risk in terms of short-term price fluctuations for MEDCL.PA.Check ORY.MC's competition here
MEDCL.PA vs ONWD.BR Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, ONWD.BR has a market cap of 197.8M. Regarding current trading prices, MEDCL.PA is priced at €17.25, while ONWD.BR trades at €4.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas ONWD.BR's P/E ratio is -5.54. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to ONWD.BR's ROE of -1.08%. Regarding short-term risk, MEDCL.PA is less volatile compared to ONWD.BR. This indicates potentially lower risk in terms of short-term price fluctuations for MEDCL.PA.Check ONWD.BR's competition here
MEDCL.PA vs HYL.BR Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, HYL.BR has a market cap of 190.4M. Regarding current trading prices, MEDCL.PA is priced at €17.25, while HYL.BR trades at €6.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas HYL.BR's P/E ratio is -29.57. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to HYL.BR's ROE of -0.19%. Regarding short-term risk, MEDCL.PA is less volatile compared to HYL.BR. This indicates potentially lower risk in terms of short-term price fluctuations for MEDCL.PA.Check HYL.BR's competition here
MEDCL.PA vs ALCLS.PA Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, ALCLS.PA has a market cap of 189.2M. Regarding current trading prices, MEDCL.PA is priced at €17.25, while ALCLS.PA trades at €2.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas ALCLS.PA's P/E ratio is -4.61. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to ALCLS.PA's ROE of -0.46%. Regarding short-term risk, MEDCL.PA is less volatile compared to ALCLS.PA. This indicates potentially lower risk in terms of short-term price fluctuations for MEDCL.PA.Check ALCLS.PA's competition here
MEDCL.PA vs GNFT.PA Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, GNFT.PA has a market cap of 180.5M. Regarding current trading prices, MEDCL.PA is priced at €17.25, while GNFT.PA trades at €3.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas GNFT.PA's P/E ratio is 120.80. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to GNFT.PA's ROE of +0.02%. Regarding short-term risk, MEDCL.PA is more volatile compared to GNFT.PA. This indicates potentially higher risk in terms of short-term price fluctuations for MEDCL.PA.Check GNFT.PA's competition here
MEDCL.PA vs IPH.PA Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, IPH.PA has a market cap of 175.9M. Regarding current trading prices, MEDCL.PA is priced at €17.25, while IPH.PA trades at €1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas IPH.PA's P/E ratio is -3.13. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to IPH.PA's ROE of -2.63%. Regarding short-term risk, MEDCL.PA is less volatile compared to IPH.PA. This indicates potentially lower risk in terms of short-term price fluctuations for MEDCL.PA.Check IPH.PA's competition here
MEDCL.PA vs ADOC.PA Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, ADOC.PA has a market cap of 146.9M. Regarding current trading prices, MEDCL.PA is priced at €17.25, while ADOC.PA trades at €8.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas ADOC.PA's P/E ratio is -8.05. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to ADOC.PA's ROE of +1.28%. Regarding short-term risk, MEDCL.PA is less volatile compared to ADOC.PA. This indicates potentially lower risk in terms of short-term price fluctuations for MEDCL.PA.Check ADOC.PA's competition here
MEDCL.PA vs OSE.PA Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, OSE.PA has a market cap of 144.5M. Regarding current trading prices, MEDCL.PA is priced at €17.25, while OSE.PA trades at €6.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas OSE.PA's P/E ratio is 4.33. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to OSE.PA's ROE of +0.52%. Regarding short-term risk, MEDCL.PA is less volatile compared to OSE.PA. This indicates potentially lower risk in terms of short-term price fluctuations for MEDCL.PA.Check OSE.PA's competition here
MEDCL.PA vs TNG.PA Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, TNG.PA has a market cap of 116.5M. Regarding current trading prices, MEDCL.PA is priced at €17.25, while TNG.PA trades at €0.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas TNG.PA's P/E ratio is -3.03. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to TNG.PA's ROE of -4.66%. Regarding short-term risk, MEDCL.PA is less volatile compared to TNG.PA. This indicates potentially lower risk in terms of short-term price fluctuations for MEDCL.PA.Check TNG.PA's competition here
MEDCL.PA vs ALSEN.PA Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, ALSEN.PA has a market cap of 108.2M. Regarding current trading prices, MEDCL.PA is priced at €17.25, while ALSEN.PA trades at €0.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas ALSEN.PA's P/E ratio is -4.00. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to ALSEN.PA's ROE of -0.33%. Regarding short-term risk, MEDCL.PA is less volatile compared to ALSEN.PA. This indicates potentially lower risk in terms of short-term price fluctuations for MEDCL.PA.Check ALSEN.PA's competition here
MEDCL.PA vs MAAT.PA Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, MAAT.PA has a market cap of 75.5M. Regarding current trading prices, MEDCL.PA is priced at €17.25, while MAAT.PA trades at €4.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas MAAT.PA's P/E ratio is -2.13. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to MAAT.PA's ROE of -1.61%. Regarding short-term risk, MEDCL.PA is less volatile compared to MAAT.PA. This indicates potentially lower risk in terms of short-term price fluctuations for MEDCL.PA.Check MAAT.PA's competition here
MEDCL.PA vs ABNX.PA Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, ABNX.PA has a market cap of 53.7M. Regarding current trading prices, MEDCL.PA is priced at €17.25, while ABNX.PA trades at €1.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas ABNX.PA's P/E ratio is -11.92. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to ABNX.PA's ROE of -0.52%. Regarding short-term risk, MEDCL.PA is less volatile compared to ABNX.PA. This indicates potentially lower risk in terms of short-term price fluctuations for MEDCL.PA.Check ABNX.PA's competition here
MEDCL.PA vs ERYP.PA Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, ERYP.PA has a market cap of 48.7M. Regarding current trading prices, MEDCL.PA is priced at €17.25, while ERYP.PA trades at €0.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas ERYP.PA's P/E ratio is -80.10. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to ERYP.PA's ROE of -0.73%. Regarding short-term risk, MEDCL.PA is less volatile compared to ERYP.PA. This indicates potentially lower risk in terms of short-term price fluctuations for MEDCL.PA.Check ERYP.PA's competition here
MEDCL.PA vs VVY.AS Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, VVY.AS has a market cap of 37.2M. Regarding current trading prices, MEDCL.PA is priced at €17.25, while VVY.AS trades at €1.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas VVY.AS's P/E ratio is -1.81. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to VVY.AS's ROE of -1.88%. Regarding short-term risk, MEDCL.PA is less volatile compared to VVY.AS. This indicates potentially lower risk in terms of short-term price fluctuations for MEDCL.PA.Check VVY.AS's competition here
MEDCL.PA vs POXEL.PA Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, POXEL.PA has a market cap of 29.7M. Regarding current trading prices, MEDCL.PA is priced at €17.25, while POXEL.PA trades at €0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas POXEL.PA's P/E ratio is -1.38. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to POXEL.PA's ROE of +0.32%. Regarding short-term risk, MEDCL.PA is less volatile compared to POXEL.PA. This indicates potentially lower risk in terms of short-term price fluctuations for MEDCL.PA.Check POXEL.PA's competition here
MEDCL.PA vs COX.PA Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, COX.PA has a market cap of 29M. Regarding current trading prices, MEDCL.PA is priced at €17.25, while COX.PA trades at €0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas COX.PA's P/E ratio is -0.46. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to COX.PA's ROE of -0.43%. Regarding short-term risk, MEDCL.PA is less volatile compared to COX.PA. This indicates potentially lower risk in terms of short-term price fluctuations for MEDCL.PA.Check COX.PA's competition here
MEDCL.PA vs ALGEN.PA Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, ALGEN.PA has a market cap of 27.5M. Regarding current trading prices, MEDCL.PA is priced at €17.25, while ALGEN.PA trades at €3.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas ALGEN.PA's P/E ratio is 12.04. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to ALGEN.PA's ROE of +0.10%. Regarding short-term risk, MEDCL.PA is more volatile compared to ALGEN.PA. This indicates potentially higher risk in terms of short-term price fluctuations for MEDCL.PA.Check ALGEN.PA's competition here
MEDCL.PA vs SIGHT.PA Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, SIGHT.PA has a market cap of 25.2M. Regarding current trading prices, MEDCL.PA is priced at €17.25, while SIGHT.PA trades at €0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas SIGHT.PA's P/E ratio is -1.09. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to SIGHT.PA's ROE of +0.54%. Regarding short-term risk, MEDCL.PA is less volatile compared to SIGHT.PA. This indicates potentially lower risk in terms of short-term price fluctuations for MEDCL.PA.Check SIGHT.PA's competition here
MEDCL.PA vs FALG.PA Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, FALG.PA has a market cap of 24M. Regarding current trading prices, MEDCL.PA is priced at €17.25, while FALG.PA trades at €0.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas FALG.PA's P/E ratio is -2.33. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to FALG.PA's ROE of -0.39%. Regarding short-term risk, MEDCL.PA is less volatile compared to FALG.PA. This indicates potentially lower risk in terms of short-term price fluctuations for MEDCL.PA.Check FALG.PA's competition here
MEDCL.PA vs DMSIM.BR Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, DMSIM.BR has a market cap of 23.1M. Regarding current trading prices, MEDCL.PA is priced at €17.25, while DMSIM.BR trades at €0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas DMSIM.BR's P/E ratio is 0.09. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to DMSIM.BR's ROE of -0.57%. Regarding short-term risk, MEDCL.PA is less volatile compared to DMSIM.BR. This indicates potentially lower risk in terms of short-term price fluctuations for MEDCL.PA.Check DMSIM.BR's competition here
MEDCL.PA vs ALVAL.PA Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, ALVAL.PA has a market cap of 21.5M. Regarding current trading prices, MEDCL.PA is priced at €17.25, while ALVAL.PA trades at €0.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas ALVAL.PA's P/E ratio is -1.44. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to ALVAL.PA's ROE of -0.74%. Regarding short-term risk, MEDCL.PA is less volatile compared to ALVAL.PA. This indicates potentially lower risk in terms of short-term price fluctuations for MEDCL.PA.Check ALVAL.PA's competition here
MEDCL.PA vs CYAD.BR Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, CYAD.BR has a market cap of 20.7M. Regarding current trading prices, MEDCL.PA is priced at €17.25, while CYAD.BR trades at €0.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas CYAD.BR's P/E ratio is -0.37. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to CYAD.BR's ROE of +0.91%. Regarding short-term risk, MEDCL.PA is less volatile compared to CYAD.BR. This indicates potentially lower risk in terms of short-term price fluctuations for MEDCL.PA.Check CYAD.BR's competition here
MEDCL.PA vs ALDVI.PA Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, ALDVI.PA has a market cap of 19.8M. Regarding current trading prices, MEDCL.PA is priced at €17.25, while ALDVI.PA trades at €1.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas ALDVI.PA's P/E ratio is -1.73. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to ALDVI.PA's ROE of +0.44%. Regarding short-term risk, MEDCL.PA is less volatile compared to ALDVI.PA. This indicates potentially lower risk in terms of short-term price fluctuations for MEDCL.PA.Check ALDVI.PA's competition here
MEDCL.PA vs ALVIO.PA Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, ALVIO.PA has a market cap of 19M. Regarding current trading prices, MEDCL.PA is priced at €17.25, while ALVIO.PA trades at €0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas ALVIO.PA's P/E ratio is -0.36. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to ALVIO.PA's ROE of -2.09%. Regarding short-term risk, MEDCL.PA is less volatile compared to ALVIO.PA. This indicates potentially lower risk in terms of short-term price fluctuations for MEDCL.PA.Check ALVIO.PA's competition here
MEDCL.PA vs ALNFL.PA Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, ALNFL.PA has a market cap of 17.4M. Regarding current trading prices, MEDCL.PA is priced at €17.25, while ALNFL.PA trades at €1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas ALNFL.PA's P/E ratio is -6.57. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to ALNFL.PA's ROE of -1.27%. Regarding short-term risk, MEDCL.PA is less volatile compared to ALNFL.PA. This indicates potentially lower risk in terms of short-term price fluctuations for MEDCL.PA.Check ALNFL.PA's competition here
MEDCL.PA vs ALPHE.PA Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, ALPHE.PA has a market cap of 15.8M. Regarding current trading prices, MEDCL.PA is priced at €17.25, while ALPHE.PA trades at €2.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas ALPHE.PA's P/E ratio is -2.67. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to ALPHE.PA's ROE of -0.64%. Regarding short-term risk, MEDCL.PA is more volatile compared to ALPHE.PA. This indicates potentially higher risk in terms of short-term price fluctuations for MEDCL.PA.Check ALPHE.PA's competition here
MEDCL.PA vs AELIS.PA Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, AELIS.PA has a market cap of 14.5M. Regarding current trading prices, MEDCL.PA is priced at €17.25, while AELIS.PA trades at €1.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas AELIS.PA's P/E ratio is -1.93. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to AELIS.PA's ROE of -0.74%. Regarding short-term risk, MEDCL.PA is less volatile compared to AELIS.PA. This indicates potentially lower risk in terms of short-term price fluctuations for MEDCL.PA.Check AELIS.PA's competition here
MEDCL.PA vs ALTHX.PA Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, ALTHX.PA has a market cap of 12.6M. Regarding current trading prices, MEDCL.PA is priced at €17.25, while ALTHX.PA trades at €1.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas ALTHX.PA's P/E ratio is -7.45. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to ALTHX.PA's ROE of +7.08%. Regarding short-term risk, MEDCL.PA is less volatile compared to ALTHX.PA. This indicates potentially lower risk in terms of short-term price fluctuations for MEDCL.PA.Check ALTHX.PA's competition here
MEDCL.PA vs BAI.AS Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, BAI.AS has a market cap of 11.2M. Regarding current trading prices, MEDCL.PA is priced at €17.25, while BAI.AS trades at €0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas BAI.AS's P/E ratio is -0.13. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to BAI.AS's ROE of -0.51%. Regarding short-term risk, MEDCL.PA is less volatile compared to BAI.AS. This indicates potentially lower risk in terms of short-term price fluctuations for MEDCL.PA.Check BAI.AS's competition here
MEDCL.PA vs ALTME.PA Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, ALTME.PA has a market cap of 10.3M. Regarding current trading prices, MEDCL.PA is priced at €17.25, while ALTME.PA trades at €0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas ALTME.PA's P/E ratio is -0.91. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to ALTME.PA's ROE of -8.99%. Regarding short-term risk, MEDCL.PA is less volatile compared to ALTME.PA. This indicates potentially lower risk in terms of short-term price fluctuations for MEDCL.PA.Check ALTME.PA's competition here
MEDCL.PA vs ALVET.PA Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, ALVET.PA has a market cap of 10M. Regarding current trading prices, MEDCL.PA is priced at €17.25, while ALVET.PA trades at €0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas ALVET.PA's P/E ratio is -0.17. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to ALVET.PA's ROE of -0.32%. Regarding short-term risk, MEDCL.PA is less volatile compared to ALVET.PA. This indicates potentially lower risk in terms of short-term price fluctuations for MEDCL.PA.Check ALVET.PA's competition here
MEDCL.PA vs ALPAT.PA Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, ALPAT.PA has a market cap of 10M. Regarding current trading prices, MEDCL.PA is priced at €17.25, while ALPAT.PA trades at €8.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas ALPAT.PA's P/E ratio is 10.72. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to ALPAT.PA's ROE of +0.11%. Regarding short-term risk, MEDCL.PA is less volatile compared to ALPAT.PA. This indicates potentially lower risk in terms of short-term price fluctuations for MEDCL.PA.Check ALPAT.PA's competition here
MEDCL.PA vs APM.PA Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, APM.PA has a market cap of 8.8M. Regarding current trading prices, MEDCL.PA is priced at €17.25, while APM.PA trades at €3.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas APM.PA's P/E ratio is -0.71. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to APM.PA's ROE of +0.08%. Regarding short-term risk, MEDCL.PA is less volatile compared to APM.PA. This indicates potentially lower risk in terms of short-term price fluctuations for MEDCL.PA.Check APM.PA's competition here
MEDCL.PA vs ALQGC.PA Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, ALQGC.PA has a market cap of 5M. Regarding current trading prices, MEDCL.PA is priced at €17.25, while ALQGC.PA trades at €0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas ALQGC.PA's P/E ratio is -0.09. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to ALQGC.PA's ROE of +14.01%. Regarding short-term risk, MEDCL.PA is less volatile compared to ALQGC.PA. This indicates potentially lower risk in terms of short-term price fluctuations for MEDCL.PA.Check ALQGC.PA's competition here
MEDCL.PA vs LYS.PA Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, LYS.PA has a market cap of 4.9M. Regarding current trading prices, MEDCL.PA is priced at €17.25, while LYS.PA trades at €0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas LYS.PA's P/E ratio is -0.64. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to LYS.PA's ROE of -11.30%. Regarding short-term risk, MEDCL.PA is more volatile compared to LYS.PA. This indicates potentially higher risk in terms of short-term price fluctuations for MEDCL.PA.Check LYS.PA's competition here
MEDCL.PA vs ALHYG.PA Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, ALHYG.PA has a market cap of 3.9M. Regarding current trading prices, MEDCL.PA is priced at €17.25, while ALHYG.PA trades at €0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas ALHYG.PA's P/E ratio is -0.26. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to ALHYG.PA's ROE of -6.80%. Regarding short-term risk, MEDCL.PA is less volatile compared to ALHYG.PA. This indicates potentially lower risk in terms of short-term price fluctuations for MEDCL.PA.Check ALHYG.PA's competition here
MEDCL.PA vs ALACT.PA Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, ALACT.PA has a market cap of 3.9M. Regarding current trading prices, MEDCL.PA is priced at €17.25, while ALACT.PA trades at €0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas ALACT.PA's P/E ratio is -0.22. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to ALACT.PA's ROE of +1.38%. Regarding short-term risk, MEDCL.PA is more volatile compared to ALACT.PA. This indicates potentially higher risk in terms of short-term price fluctuations for MEDCL.PA.Check ALACT.PA's competition here
MEDCL.PA vs ALBPS.PA Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, ALBPS.PA has a market cap of 3.7M. Regarding current trading prices, MEDCL.PA is priced at €17.25, while ALBPS.PA trades at €0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas ALBPS.PA's P/E ratio is -0.11. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to ALBPS.PA's ROE of +1.88%. Regarding short-term risk, MEDCL.PA is less volatile compared to ALBPS.PA. This indicates potentially lower risk in terms of short-term price fluctuations for MEDCL.PA.Check ALBPS.PA's competition here
MEDCL.PA vs ALMDP.PA Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, ALMDP.PA has a market cap of 1.8M. Regarding current trading prices, MEDCL.PA is priced at €17.25, while ALMDP.PA trades at €0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas ALMDP.PA's P/E ratio is -0.59. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to ALMDP.PA's ROE of +0.40%. Regarding short-term risk, MEDCL.PA is less volatile compared to ALMDP.PA. This indicates potentially lower risk in terms of short-term price fluctuations for MEDCL.PA.Check ALMDP.PA's competition here
MEDCL.PA vs ALINT.PA Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, ALINT.PA has a market cap of 1.8M. Regarding current trading prices, MEDCL.PA is priced at €17.25, while ALINT.PA trades at €0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas ALINT.PA's P/E ratio is -6.75. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to ALINT.PA's ROE of -0.14%. Regarding short-term risk, MEDCL.PA is less volatile compared to ALINT.PA. This indicates potentially lower risk in terms of short-term price fluctuations for MEDCL.PA.Check ALINT.PA's competition here
MEDCL.PA vs BIOS.BR Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, BIOS.BR has a market cap of 1.6M. Regarding current trading prices, MEDCL.PA is priced at €17.25, while BIOS.BR trades at €0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas BIOS.BR's P/E ratio is -0.06. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to BIOS.BR's ROE of +0.34%. Regarding short-term risk, MEDCL.PA is less volatile compared to BIOS.BR. This indicates potentially lower risk in terms of short-term price fluctuations for MEDCL.PA.Check BIOS.BR's competition here
MEDCL.PA vs ALDEI.PA Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, ALDEI.PA has a market cap of 1.1M. Regarding current trading prices, MEDCL.PA is priced at €17.25, while ALDEI.PA trades at €0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas ALDEI.PA's P/E ratio is -0.11. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to ALDEI.PA's ROE of +0.61%. Regarding short-term risk, MEDCL.PA is less volatile compared to ALDEI.PA. This indicates potentially lower risk in terms of short-term price fluctuations for MEDCL.PA.Check ALDEI.PA's competition here
MEDCL.PA vs OVXA.IR Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, OVXA.IR has a market cap of 856.4K. Regarding current trading prices, MEDCL.PA is priced at €17.25, while OVXA.IR trades at €0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas OVXA.IR's P/E ratio is -0.21. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to OVXA.IR's ROE of -0.00%. Regarding short-term risk, MEDCL.PA is more volatile compared to OVXA.IR. This indicates potentially higher risk in terms of short-term price fluctuations for MEDCL.PA.Check OVXA.IR's competition here
MEDCL.PA vs GNRO.PA Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, GNRO.PA has a market cap of 802K. Regarding current trading prices, MEDCL.PA is priced at €17.25, while GNRO.PA trades at €0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas GNRO.PA's P/E ratio is -0.05. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to GNRO.PA's ROE of +2.39%. Regarding short-term risk, MEDCL.PA is less volatile compared to GNRO.PA. This indicates potentially lower risk in terms of short-term price fluctuations for MEDCL.PA.Check GNRO.PA's competition here
MEDCL.PA vs OXUR.BR Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, OXUR.BR has a market cap of 640.6K. Regarding current trading prices, MEDCL.PA is priced at €17.25, while OXUR.BR trades at €0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas OXUR.BR's P/E ratio is N/A. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to OXUR.BR's ROE of -0.01%. Regarding short-term risk, MEDCL.PA is less volatile compared to OXUR.BR. This indicates potentially lower risk in terms of short-term price fluctuations for MEDCL.PA.Check OXUR.BR's competition here
MEDCL.PA vs ALNEV.PA Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, ALNEV.PA has a market cap of 562.4K. Regarding current trading prices, MEDCL.PA is priced at €17.25, while ALNEV.PA trades at €1.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas ALNEV.PA's P/E ratio is -0.01. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to ALNEV.PA's ROE of -1.79%. Regarding short-term risk, MEDCL.PA is less volatile compared to ALNEV.PA. This indicates potentially lower risk in terms of short-term price fluctuations for MEDCL.PA.Check ALNEV.PA's competition here
MEDCL.PA vs ALPHA.PA Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, ALPHA.PA has a market cap of 1.2K. Regarding current trading prices, MEDCL.PA is priced at €17.25, while ALPHA.PA trades at €0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas ALPHA.PA's P/E ratio is -0.00. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to ALPHA.PA's ROE of +0.83%. Regarding short-term risk, MEDCL.PA is less volatile compared to ALPHA.PA. This indicates potentially lower risk in terms of short-term price fluctuations for MEDCL.PA.Check ALPHA.PA's competition here
MEDCL.PA vs ACPH.BR Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, ACPH.BR has a market cap of 0. Regarding current trading prices, MEDCL.PA is priced at €17.25, while ACPH.BR trades at €0.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas ACPH.BR's P/E ratio is -1.40. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to ACPH.BR's ROE of -1.55%. Regarding short-term risk, MEDCL.PA is more volatile compared to ACPH.BR. This indicates potentially higher risk in terms of short-term price fluctuations for MEDCL.PA.Check ACPH.BR's competition here
MEDCL.PA vs GKTX.PA Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, GKTX.PA has a market cap of 0. Regarding current trading prices, MEDCL.PA is priced at €17.25, while GKTX.PA trades at €3.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas GKTX.PA's P/E ratio is -2.56. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to GKTX.PA's ROE of -2.26%. Regarding short-term risk, MEDCL.PA is more volatile compared to GKTX.PA. This indicates potentially higher risk in terms of short-term price fluctuations for MEDCL.PA.Check GKTX.PA's competition here
MEDCL.PA vs ADVIC.PA Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, ADVIC.PA has a market cap of 0. Regarding current trading prices, MEDCL.PA is priced at €17.25, while ADVIC.PA trades at €6.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas ADVIC.PA's P/E ratio is -3.67. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to ADVIC.PA's ROE of +0.44%. Regarding short-term risk, MEDCL.PA is less volatile compared to ADVIC.PA. This indicates potentially lower risk in terms of short-term price fluctuations for MEDCL.PA.Check ADVIC.PA's competition here
MEDCL.PA vs ALIMM.BR Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, ALIMM.BR has a market cap of 0. Regarding current trading prices, MEDCL.PA is priced at €17.25, while ALIMM.BR trades at €0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas ALIMM.BR's P/E ratio is -2.23. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to ALIMM.BR's ROE of -0.92%. Regarding short-term risk, MEDCL.PA is less volatile compared to ALIMM.BR. This indicates potentially lower risk in terms of short-term price fluctuations for MEDCL.PA.Check ALIMM.BR's competition here
MEDCL.PA vs VLAP.PA Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, VLAP.PA has a market cap of 0. Regarding current trading prices, MEDCL.PA is priced at €17.25, while VLAP.PA trades at €0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas VLAP.PA's P/E ratio is -0.10. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to VLAP.PA's ROE of -0.43%. Regarding short-term risk, MEDCL.PA is less volatile compared to VLAP.PA. This indicates potentially lower risk in terms of short-term price fluctuations for MEDCL.PA.Check VLAP.PA's competition here
MEDCL.PA vs BOTHE.BR Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, BOTHE.BR has a market cap of 0. Regarding current trading prices, MEDCL.PA is priced at €17.25, while BOTHE.BR trades at €0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas BOTHE.BR's P/E ratio is -0.38. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to BOTHE.BR's ROE of +7.51%. Regarding short-term risk, MEDCL.PA is less volatile compared to BOTHE.BR. This indicates potentially lower risk in terms of short-term price fluctuations for MEDCL.PA.Check BOTHE.BR's competition here
MEDCL.PA vs ALONC.PA Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, ALONC.PA has a market cap of 0. Regarding current trading prices, MEDCL.PA is priced at €17.25, while ALONC.PA trades at €14.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas ALONC.PA's P/E ratio is 63.25. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to ALONC.PA's ROE of -0.09%. Regarding short-term risk, MEDCL.PA is more volatile compared to ALONC.PA. This indicates potentially higher risk in terms of short-term price fluctuations for MEDCL.PA.Check ALONC.PA's competition here
MEDCL.PA vs ASIT.BR Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, ASIT.BR has a market cap of 0. Regarding current trading prices, MEDCL.PA is priced at €17.25, while ASIT.BR trades at €0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas ASIT.BR's P/E ratio is -32.71. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to ASIT.BR's ROE of +0.38%. Regarding short-term risk, MEDCL.PA is less volatile compared to ASIT.BR. This indicates potentially lower risk in terms of short-term price fluctuations for MEDCL.PA.Check ASIT.BR's competition here
MEDCL.PA vs ALNOX.PA Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, ALNOX.PA has a market cap of 0. Regarding current trading prices, MEDCL.PA is priced at €17.25, while ALNOX.PA trades at €0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas ALNOX.PA's P/E ratio is -0.19. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to ALNOX.PA's ROE of -2.36%. Regarding short-term risk, MEDCL.PA is less volatile compared to ALNOX.PA. This indicates potentially lower risk in terms of short-term price fluctuations for MEDCL.PA.Check ALNOX.PA's competition here
MEDCL.PA vs ORPH.IR Comparison July 2025
MEDCL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDCL.PA stands at 570.6M. In comparison, ORPH.IR has a market cap of 0. Regarding current trading prices, MEDCL.PA is priced at €17.25, while ORPH.IR trades at €0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDCL.PA currently has a P/E ratio of -15.83, whereas ORPH.IR's P/E ratio is N/A. In terms of profitability, MEDCL.PA's ROE is +0.66%, compared to ORPH.IR's ROE of -0.00%. Regarding short-term risk, MEDCL.PA is more volatile compared to ORPH.IR. This indicates potentially higher risk in terms of short-term price fluctuations for MEDCL.PA.Check ORPH.IR's competition here